NPPA fixed retail price of 28 formulations: November 2025

Last Updated on January 13, 2026 by The Health Master

NPPA

Download NPPA notification No. S.O. 5017(E) dt 04-11-2025, the link is given below: The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 28 formulations under the Drugs (Prices Control) Order, 2013, vide S.O. 5017 (E) dt 04-11-2025 based on the decision of 138th Authority meeting dated 30-10-2025.

The notification states as follows:

In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

A table is given below the article

Note:

(a) The manufacturer of the above-mentioned formulations, i.e., the “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have actually paid it or it is payable to the Government on the retail price mentioned in column (6) of the above-mentioned table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013.

The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above, i.e., those who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to the fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes or rules, including manufacturing license permission from the competent authority, i.e., the central or state licensing authority, as may be applicable, by the concerned manufacturer/marketing company.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per the instant price notification and notes specified hereinabove, then the concerned manufacturer / marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of the manufacturer and marketing company specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer and marketing company Companies as specified in corresponding entries in Columns (2), (3), and (5) thereof, if any, issued prior to this notification, stand superseded.

Table

Sl. No.	Medicine	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1	Amlodipine & Valsartan Tablets	Each film coated tablet contains: Amlodipine besylate IP eq. to Amlodipine 5 mg Valsartan IP 80 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Alembic Pharmaceuticals Ltd.	7.41
2	Dapagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets	Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP Eq. to Dapagliflozin 10 mg Sitagliptin Phosphate Monohydrate IP Eq. to Sitagliptin 100 mg Metformin Hydrochloride IP 500 mg (As extended release form)	1 Tablet	M/s Windlas Biotech Ltd. / M/s Jagsonpal Pharmaceuticals Ltd.	18.18
3	Empagliflozin, Linagliptin & Metformin Hydrochloride Extended Release Tablets	Each film coated bilayer tablet contains: Empagliflozin 10mg Linagliptin 5 mg Metformin Hydrochloride (Extended Release) IP 1000 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Corona Remedies Pvt. Ltd.	29.21
4	Empagliflozin, Sitagliptin and Metformin Hydrochloride Extended Release Tablets	Each film coated bilayer tablet contains: Empagliflozin 25 mg Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg, Metformin Hydrochloride (As Extended Release) IP 1000 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Alembic Pharmaceuticals Ltd.	25.00
5	Levocetirizine Hydrochloride & Montelukast Syrup	Each 5 ml contains: Levocetirizine Hydrochloride IP 2.5 mg Montelukast Sodium IP eq. to Montelukast 5 mg	1 ml	M/s Ravenbhel Healthcare Pvt. Ltd. M/s Cipla Ltd.	1.88
6	Linagliptin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Linagliptin 5 mg Metformin Hydrochloride IP 500 mg (As extended-release form)	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd.	10.09
7	Metoprolol succinate Extended Release, Amlodipine & Telmisartan Tablets	Each film coated bilayered tablet contains: Metoprolol succinate IP 23.75 mg eq. to Metoprolol Tartrate 25 mg (As extended release) Amlodipine Besilate IP eq to Amlodipine 5 mg Telmisartan IP 40 mg	1 Tablet	M/s Ajanta Pharma Ltd./ M/s Sun Pharma Laboratories Ltd.	13.01
8	Mefenamic acid & Paracetamol Tablets	Each uncoated tablet contains: Mefenamic Acid IP 500 mg Paracetamol IP 325 mg	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Dr. Reddy’s Laboratories Ltd.	3.91
9	S (-) Pantoprazole for Injection (Lyophilized)	Each vial contains: S (-) Pantoprazole Sodium equivalent to S (-) Pantoprazole 20mg	1 Vial	M/s Gufic Biosciences Ltd.	118.39
10	S (-) Pantoprazole for Injection (Lyophilized)	Each vial contains: S (-) Pantoprazole Sodium equivalent to S (-) Pantoprazole 20mg	1 Vial	M/s Gufic Biosciences Ltd./ M/s Tyykem Pvt. Ltd.	118.39

11	Paracetamol & Caffeine Tablets	Each uncoated tablet contains: Paracetamol IP 650 mg Caffeine IP 50 mg	1 Tablet	M/s Psychotropics India Ltd.	4.01
12	Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg, Glimepiride IP 1 mg, Metformin Hydrochloride IP 1000 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Ipca Laboratories Ltd.	11.18
13	Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg, Glimepiride IP 2 mg, Metformin Hydrochloride IP 1000 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Ipca Laboratories Ltd.	12.78
14	Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg, Glimepiride IP 1 mg, Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Ipca Laboratories Ltd.	13.24
15	Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg, Glimepiride IP 2 mg, Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Ipca Laboratories Ltd.	14.92
16	Alginate Raft- forming Oral Suspension BP	Each 5ml contains: Sodium Alginate IP 250 mg Sodium Bicarbonate IP 133.5 mg Calcium Carbonate IP 80 mg	1 ml	M/s Skymap Pharmaceuticals Pvt. Ltd. M/s German Remedies Pharmaceuticals Pvt. Ltd.	0.95
17	Telmisartan & Amlodipine Tablets	Each uncoated bilayered tablet contains: Telmisartan IP 40 mg Amlodipine Besilate IP 5 mg	1 Tablet	M/s Swiss Garnier Life Sciences/ M/s SRK Puremed LLP	7.14
18	Telmisartan & Amlodipine Tablets	Each uncoated bilayered tablet contains: Telmisartan IP 80 mg Amlodipine Besilate Equivalent to Amlodipine IP 5 mg	1 Tablet	M/s Swiss Garnier Life Sciences/ M/s SRK Puremed LLP	9.82
19	Telmisartan & Chlorthalidone Tablets	Each uncoated tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 12.5 mg	1 Tablet	M/s Swiss Garnier Life Sciences/ M/s SRK Puremed LLP	8.93
20	Telmisartan & Chlorthalidone Tablets	Each uncoated tablet contains: Telmisartan IP 80 mg Chlorthalidone IP 12.5 mg	1 Tablet	M/s Swiss Garnier Life Sciences/ M/s SRK Puremed LLP	11.16

21	Telmisartan, Cilnidipine and Metoprolol Succinate (ER) Tablets	Each film coated bilayered tablet contains: Telmisartan IP 40 mg Cilnidipine IP 10 mg Metoprolol Succinate IP 23.75 mg eq. to Metoprolol Tartrate (As extended release) 25 mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd.	11.39
22	Telmisartan, Cilnidipine and Metoprolol Succinate (ER) Tablets	Each film coated bilayered tablet contains: Telmisartan IP 40 mg Cilnidipine IP 10 mg Metoprolol Succinate IP 47.50 mg eq. to Metoprolol Tartrate (As extended release) 50 mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd.	14.35
23	Telmisartan & Hydrochlorothiazide Tablets	Each uncoated tablet contains: Telmisartan IP 80 mg Hydrochlorothiazide IP 12.5 mg	1 Tablet	M/s Unison Pharmaceuticals Pvt. Ltd.	14.00
24	Telmisartan & Hydrochlorothiazide Tablets	Each uncoated bilayered tablet contains: Telmisartan IP 80 mg Hydrochlorothiazide IP 12.5 mg	1 Tablet	M/s Swiss Garnier Life Sciences/ M/s SRK Puremed LLP	10.29
25	Theophylline Anhydrous (SR) & Montelukast Sodium Tablets	Each Film coated Tablet Contains: Theophylline (Anhydrous) IP 400 mg (as sustained release) Montelukast Sodium IP Equivalent to Montelukast 10 mg	1 Tablet	M/s East African (I) Overseas/ M/s Zydus Healthcare Ltd.	13.78
26	Amoxycillin & Potassium Clavulanate tablets	Each film coated tablet contains: Amoxycillin Trihydrate IP Equivalent to Amoxycillin 875 mg Potassium Clavulanate Diluted IP Equivalent to Clavulanic Acid 125 mg	1 Tablet	M/s Alps Communication Pvt. Ltd./ M/s Indoco Remedies Ltd.	42.84
27	Teneligliptin, Dapagliflozin, Metformin (Sustained Release) Tablets	Each film-coated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20 mg, Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10 mg, Metformin Hydrochloride I.P 1000 mg (As Sustained Release)	1 Tablet	M/s Synokem Lifesciences Pvt. Ltd / M/s Glenmark Pharmaceuticals Ltd.	13.39
28	Povidone Iodine alcoholic prep solution 10% w/v	Povidone Iodine IP 10.0% w/v (available Iodine 1.0% w/v) Ethanol IP 30% v/v	1 ml	M/s G.S. Pharmbutor Pvt. Ltd./ M/s Win-Medicare Pvt. Ltd.	1.14

• IP 2026 released: Salient Features
  January 7, 2026
• Drug alert: 205 drug samples declared as NSQ in November 2025
  December 25, 2025
• FDA Haryana is Redefining Drug Safety and MSMEs Growth
  December 17, 2025
• 10th edition of IP for standards of drugs in India
  December 9, 2025
• QR Code mandatory at every Medical Store for ADR reporting
  November 26, 2025
• Landmark Seminar by FDA Haryana on Spurious drugs and NDPS Misuse
  November 25, 2025